Newsroom

NEWSROOM

November 19, 2020

Galderma launches Dysport® in China for treatment of glabellar lines

November 18, 2020 Dysport® is a prescription injection for temporary improvement in the look of moderate to severe glabellar lines.
November 19, 2020

Galderma Announces Top-line Results from Phase 2 Clinical Dose-Escalating Study with Azzalure® / Dysport® (abobotulinumtoxinA)

November 17, 2020 Phase 2 study on the impact of dose escalation on the duration of effect, efficacy and safety of a single dose of Dysport®
November 6, 2020

Galderma To Present Five Abstracts in Support of Novel Aesthetics Solutions and Pipeline at ASDS 2020 Annual Meeting

October 9, 2020 Phase 3 READY program of its proprietary, liquid formulation of an investigational botulinum toxin is fully enrolled.
October 29, 2020

Galderma receives approval for Restylane® Vital™, Restylane® Lyft™, and Restylane® Lidocaine in China

April 22, 2020 First approval for a class III medical device for improved skin appearance in China. 

October 29, 2020

Galderma demonstrates continued commitment to aesthetic education by offering new series of digital webinars*

April 15, 2020 Business-building webinars to support local Aesthetic practices. Expert injector techniques by GAIN faculty.
October 29, 2020

Galderma Demonstrates Robust Aesthetic Innovation Pipeline with Initiation of Seven New Clinical Studies

October 24, 2019 Ten Data Releases Will Be Presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting.
October 29, 2020

Galderma´s Azzalure and Dysport® celebrate a decade of treatment of the glabellar lines

April 4, 2019 Azzalure (marketed as Dysport outside of the EU) for the treatment of glabellar lines marks 10 year anniversary.